Citius Oncology, Inc. Cash Flow Quality Index
Citius Oncology, Inc. cash flow quality index. Citius Oncology, Inc. (CTOR) has a Cash Flow Quality Index of -1.44x as of June 2024. Operating cash flow of $-364.06K is below net income of $252.46K, suggesting accrual-heavy earnings not yet converted to cash. See financial agility of Citius Oncology, Inc. to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Citius Oncology, Inc. (2022–2023)
Cash flow quality index of Citius Oncology, Inc. from 2022 to 2023. Historical Cash Flow Quality Index for Citius Oncology, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Citius Oncology, Inc. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Citius Oncology, Inc. Cash Flow Quality Index by Year (2022–2023)
Citius Oncology, Inc. cash flow quality index by year from 2022 to 2023. Year-by-year earnings quality comparison for Citius Oncology, Inc.. For the full cash flow conversion analysis, see Citius Oncology, Inc. operating cash flow efficiency.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | -0.25x | $-601.30K | $2.42 Million | ▼ -97.3% |
| 2022 | -0.13x | $-47.97K | $380.81K | — |